arrow

From NeuroLex

Jump to: navigation, search



Alemtuzumab

Name: Alemtuzumab
Description: Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Pharmacology: Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations. Mechanism of action: Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells. Drug type: Approved. Biotech. Investigational. Drug category: Antineoplastic Agents
Synonym(s): alemtuzumab, Campath, Campath (ILEX Pharmaceuticals LP), MabCampath
Has role: Drug
Super-category: Molecular entity
URL: http://www.drugbank.ca/drugs/DB00087
*Id: DB00087
Related to: CAMPATH-1 antigen, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c
Link to OWL / RDF: Download this content as OWL/RDF


Contributors

Ccdbuser, Nifbot2



bookmark

*Note: Neurolex imports many terms and their ids from existing community ontologies, e.g., the Gene Ontology. Neurolex, however, is a dynamic site and any content beyond the identifier should not be presumed to reflect the content or views of the source ontology. Users should consult with the authoritative source for each ontology for current information.

Facts about AlemtuzumabRDF feed
Commenttaken from DrugBank
CuratorAb  +
DefiningCitationhttp://www.drugbank.ca/drugs/DB00087  +
DefinitionHumanized monoclonal antibody specific to Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Pharmacology: Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations. Mechanism of action: Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells. Drug type: Approved. Biotech. Investigational. Drug category: Antineoplastic Agents onal. Drug category: Antineoplastic Agents
Has roleDrug  +
IdDB00087  +
LabelAlemtuzumab  +
ModifiedDate14 April 2014  +
RelatedToCAMPATH-1 antigen  +, High affinity immunoglobulin gamma Fc receptor I  +, Low affinity immunoglobulin gamma Fc region receptor III-B  +, Complement C1r subcomponent  +, Complement C1q subcomponent subunit A  +, Complement C1q subcomponent subunit B  +, Complement C1q subcomponent subunit C  +, Low affinity immunoglobulin gamma Fc region receptor III-A  +, Low affinity immunoglobulin gamma Fc region receptor II-a  +, Low affinity immunoglobulin gamma Fc region receptor II-b  +, and Low affinity immunoglobulin gamma Fc region receptor II-c  +
SuperCategoryMolecular entity  +
Synonymalemtuzumab  +, Campath  +, Campath (ILEX Pharmaceuticals LP)  +, and MabCampath  +